Normal Human Serum Complement (5.0 mL)

Uniform pool of human serum complement that has been characterized for levels of complement activation fragments as well as CH50.


Product Specifications

Citations35
Description

Uniform pool of human serum complement that has been characterized for levels of complement activation fragments as well as CH50.

Storage

Store at or below –70˚C

Form

Frozen Liquid

Concentration

N/A

Applications

See citations and technical data sheet for application info.

Ordering Information

For Research Use Only. Not for use in diagnostic procedures.
Catalog NumberA113
Catalog Number (CE)N/A
Size5.0 mL
Price (USD)$340.00
Price (EURO)305,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

Uniform pool of human serum complement that has been characterized for levels of complement activation fragments as well as CH50.

Size5.0 mL
Storage

Store at or below –70˚C

Form

Frozen Liquid

ConcentrationN/A
ApplicationsSee citations and technical data sheet for application info.
PurityN/A
SourceHuman blood
ActivityN/A
Molecular WeightN/A
Background

Because the anticoagulants used in the preparation of plasma (EDTA, ACD and even heparin) can interfere with complement activation in vitro, serum has long been used as a human complement source for experimentation. Many commercially available sera, however, are not processed appropriately to conserve complement activity. Lyophilization and plasma recalcification can raise background levels of complement split products (SC5b-9 or TCC, iC3b, Bb, C4d and particularly the anaphylatoxins C3a, C5a and C4a) and decrease CH50. Sera, however, must be processed quickly and correctly to prevent complement turnover. For this reason, sera obtained from blood banks and other large pools may not be suitable for many experimental procedures. Conversely, in house serum draws are complicated by several factors including the necessity of maintaining standardized pools of complement for ongoing experimentation and the confidentiality requirements relating to infectious disease testing. QuidelOrtho Normal Human Serum Complement is designed to address these specific issues.

Citations

TitleYearApplicationsSample SpeciesSampleSample Details

Interleukin-1β and cathepsin D modulate formation of the terminal complement complex in cultured human disc tissue.

2021Complement Activation AssayHuman

Disc Tissue

N/A

Analytical Similarity Assessment of ABP 959 in Comparison with Eculizumab Reference Product.

2021ELISAHuman

Serum

N/A

Antigenic Variation in Streptococcus pneumoniae PspC Promotes Immune Escape in the Presence of Variant-Specific Immunity.

2018FCBacteria

Streptococcus pneumoniae

N/A

T0001, a variant of TNFR2-Fc fusion protein, exhibits improved Fc effector functions through increased binding to membrane-bound TNFα.

2017CDC AssayCell Culture

CHO cells

N/A

A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action.

2017CDC AssayHuman

A549 cells

N/A

A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action.

2017CDC AssayHuman

WIL2-S cells

N/A

Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs.

2017FCHuman

Peripheral blood mononuclear cells

N/A

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®.

2016CDC AssayCell Culture

KIT225/K6 cells

N/A

Recruitment of Factor H to the Streptococcus suis Cell Surface is Multifactorial.

2016Phagocytosis assayCell Culture

THP-1 Cells

N/A

A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus.

2015CDC AssayCell Culture

CHO Cells

N/A

Complement-Opsonized HIV-1 Overcomes Restriction in Dendritic Cells.

2015ELISAVirus

HIV

Purified

Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.

2014CDC AssayCell Culture

Daudi Cells

N/A

Comparability of a three-dimensional structure in biopharmaceuticals using spectroscopic methods.

2014CDC AssayCell Culture

WIL2-S cells

N/A

The Vi capsular polysaccharide enables Salmonella enterica serovar typhi to evade microbe-guided neutrophil chemotaxis.

2014ELISABacteria

Salmonella enterica

N/A

Bioactive lysophospholipids generated by hepatic lipase degradation of lipoproteins lead to complement activation via the classical pathway

2014ELISAHuman

Serum

N/A

Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles

2013CDC AssayCell Culture

Huh7.5 Cells

N/A

Real time assays for quantifying cytotoxicity with single cell resolution.

2013CDC AssayCell Culture

Jeko-1 Cells

Lymphoma cells

Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.

2013CDC AssayCell Culture

MDA-MB-231 Cells

N/A

The Natural Human IgM Antibody PAT-SM6 Induces Apoptosis in Primary Human Multiple Myeloma Cells by Targeting Heat Shock Protein GRP80

2013CDC AssayCell Culture

OPM-2 cells

N/A

Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others

2013CDC AssayCell Culture

RC-K8 cells

N/A

Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others

2013CDC AssayCell Culture

SU-DHL-4 cells

N/A

Loss of very-long O-antigen chains optimizes capsule-mediated immune evasion by Salmonella enterica serovar Typhi.

2013FCBacteria

Salmonella enterica

N/A

Complement c5a generation by staphylococcal biofilms

2013FCHuman

Serum

Staphylococcus epidermidis incubated

Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction

2013Mass SpecHuman

Red Blood Cells

N/A

Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.

2012CDC AssayHuman

Peripheral blood mononuclear cells

N/A

Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities

2012CDC AssayHuman

WIL2-S cells

CD-20 AbX antibody

Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement

2012TER MeasurementsCell Culture

RPE Cells

N/A

Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes

2012VCAVirus

HIV

Purified

Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity

2011CDC AssayCell Culture

sLea antigen

positive and negative cell lines

Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys

2011CDC AssayHuman

B-Cells

N/A

Humanization and characterization of an anti-human TNF-α murine monoclonal antibody.

2011CDC AssayHuman

Peripheral blood mononuclear cells

N/A

Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury

2009TER MeasurementsHuman

ARPE-19 Cells

N/A

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action

2008CDC AssayCell Culture

Daudi Cells

N/A

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action

2008CDC AssayCell Culture

Ramos Cells

N/A

Engineered antibody Fc variants with enhanced effector function

2006CDC AssayHuman

WIL2-S cells

Rituximab